Loading...
As neoadjuvant therapy becomes increasingly common before breast cancer surgery, the results of this important and novel study must be considered. Texas researchers retrospectively analyzed 706 breast cancer patients (stages I-III) who were treated with neoadjuvant anthracycline-based chemotherapy and stage-appropriate locoregional therapy to determine their clinical outcomes. Ninety-seven patients (13.7%) had clinical multifocal or multicentric (MFMC) breast cancer. Mean follow-up was 66 months. The MFMC and unicentric groups had similar patient and tumor characteristics (patient age, tumor nuclear grade, tumor stage, lymph node stage, overall stage, and estrogen-receptor status).
The 5-year rate of locoregional failure was 10% for unicentr…